StockData
Axsome Therapeutics, Inc. logo

Axsome Therapeutics, Inc. (AXSM) stock

AXSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 2, 2026Score 8/30
$134.00−1.95 (-1.43%)

Close on Nov 18, 2026Market cap $7.02BP/E –Yield –

Axsome Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Axsome Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$71.26M. For fiscal 2025 it was -$93.41M. The highest annual figure on record is -$4.60M in fiscal 2014.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$93.41M–
FY2024Dec 31, 2024-$128.41M–
FY2023Dec 31, 2023-$145.08M–
FY2022Dec 31, 2022-$116.51M–
FY2021Dec 31, 2021-$108.23M–
FY2020Dec 31, 2020-$78.46M–
FY2019Dec 31, 2019-$46.38M–
FY2018Dec 31, 2018-$30.05M–
FY2017Dec 31, 2017-$26.47M–
FY2016Dec 31, 2016-$21.28M–
FY2015Dec 31, 2015-$7.44M–
FY2014Dec 31, 2014-$4.60M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$32.95M–
Q1 FY2026Mar 31, 2026-$20.70M–
Q4 FY2025Dec 31, 2025-$18.65M–
Q3 FY2025Sep 30, 2025$1.05M–
Q2 FY2025Jun 30, 2025-$32.42M–
Q1 FY2025Mar 31, 2025-$43.38M–
Q4 FY2024Dec 31, 2024-$26.20M–
Q3 FY2024Sep 30, 2024-$18.63M–
Q2 FY2024Jun 30, 2024-$30.11M–
Q1 FY2024Mar 31, 2024-$53.47M–
Q4 FY2023Dec 31, 2023-$30.36M–
Q3 FY2023Sep 30, 2023-$53.55M–
Q2 FY2023Jun 30, 2023-$55.35M–
Q1 FY2023Mar 31, 2023-$5.82M–
Q4 FY2022Dec 31, 2022-$27.56M–
Q3 FY2022Sep 30, 2022-$22.76M–
Q2 FY2022Jun 30, 2022-$33.54M–
Q1 FY2022Mar 31, 2022-$32.65M–
Q4 FY2021Dec 31, 2021-$28.84M–
Q3 FY2021Sep 30, 2021-$26.78M–
Q2 FY2021Jun 30, 2021-$25.39M–
Q1 FY2021Mar 31, 2021-$27.22M–
Q4 FY2020Dec 31, 2020-$20.55M–
Q3 FY2020Sep 30, 2020-$15.73M–
Q2 FY2020Jun 30, 2020-$18.90M–
Q1 FY2020Mar 31, 2020-$23.27M–
Q4 FY2019Dec 31, 2019-$17.57M–
Q3 FY2019Sep 30, 2019-$10.63M–
Q2 FY2019Jun 30, 2019-$8.68M–
Q1 FY2019Mar 31, 2019-$9.50M–
Q4 FY2018Dec 31, 2018-$9.79M–
Q3 FY2018Sep 30, 2018-$5.91M–
Q2 FY2018Jun 30, 2018-$7.67M–
Q1 FY2018Mar 31, 2018-$6.68M–
Q4 FY2017Dec 31, 2017-$6.29M–
Q3 FY2017Sep 30, 2017-$6.45M–
Q2 FY2017Jun 30, 2017-$7.10M–
Q1 FY2017Mar 31, 2017-$6.64M–
Q4 FY2016Dec 31, 2016-$7.22M–
Q3 FY2016Sep 30, 2016-$4.80M–

More Axsome Therapeutics figures

See a number that looks wrong?